JP2021502329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502329A5 JP2021502329A5 JP2020520153A JP2020520153A JP2021502329A5 JP 2021502329 A5 JP2021502329 A5 JP 2021502329A5 JP 2020520153 A JP2020520153 A JP 2020520153A JP 2020520153 A JP2020520153 A JP 2020520153A JP 2021502329 A5 JP2021502329 A5 JP 2021502329A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- cancer
- items
- agent
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 50
- 206010028980 Neoplasm Diseases 0.000 description 34
- 201000011510 cancer Diseases 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 22
- 101150111584 RHOA gene Proteins 0.000 description 16
- 102100022387 Transforming protein RhoA Human genes 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000009169 immunotherapy Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 7
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 6
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000000423 cell based assay Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 238000011275 oncology therapy Methods 0.000 description 6
- -1 ICOS Proteins 0.000 description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 208000024334 diffuse gastric cancer Diseases 0.000 description 4
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 102100036008 CD48 antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 description 2
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 2
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 description 2
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 2
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
- 206010050017 Lung cancer metastatic Diseases 0.000 description 2
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101150036449 SIRPA gene Proteins 0.000 description 2
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 description 2
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762583166P | 2017-11-08 | 2017-11-08 | |
| US62/583,166 | 2017-11-08 | ||
| PCT/US2018/059188 WO2019094326A1 (en) | 2017-11-08 | 2018-11-05 | Compositions and methods for treating cancer using rhoa dominant negative forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502329A JP2021502329A (ja) | 2021-01-28 |
| JP2021502329A5 true JP2021502329A5 (https=) | 2021-12-16 |
Family
ID=66439269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520153A Pending JP2021502329A (ja) | 2017-11-08 | 2018-11-05 | Ｒｈｏａドミナントネガティブフォームを使用して癌を治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11957739B2 (https=) |
| EP (1) | EP3706751A4 (https=) |
| JP (1) | JP2021502329A (https=) |
| CN (1) | CN111278443A (https=) |
| AU (1) | AU2018365800A1 (https=) |
| CA (1) | CA3076269A1 (https=) |
| WO (1) | WO2019094326A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11957739B2 (en) | 2017-11-08 | 2024-04-16 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer using RHOA dominant negative forms |
| SE2000055A1 (sv) * | 2020-03-15 | 2021-09-16 | Martin Ivanov Denev | Användande av fotohydrauliskt mekanisk chock, för selektiv sprängning av relativ svagare cellmembranen av cancerceller, vilka har svagare cellmembran än friska celler |
| CN113278706B (zh) * | 2021-07-23 | 2021-11-12 | 广州燃石医学检验所有限公司 | 一种用于区分体细胞突变和种系突变的方法 |
| WO2024059823A1 (en) * | 2022-09-15 | 2024-03-21 | Iview Therapeutics, Inc. | Self-complementary AAV vectors carrying dominant negative RhoA and methods of use to treat ocular diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1274463A2 (en) * | 1999-12-10 | 2003-01-15 | Whitehead Institute For Biomedical Research | Metastasis genes and uses thereof |
| WO2003030836A2 (en) * | 2001-10-12 | 2003-04-17 | Case Western Reserve University | Neuronal regeneration |
| WO2005072141A2 (en) * | 2004-01-16 | 2005-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Peptide inhibitors of rhoa signaling |
| US7951924B2 (en) | 2004-11-12 | 2011-05-31 | University Of South Florida | RhoB variants and methods of use |
| US7507534B2 (en) | 2005-09-01 | 2009-03-24 | National Health Research Institutes | Rapid efficacy assessment method for lung cancer therapy |
| US20070161060A1 (en) | 2005-09-07 | 2007-07-12 | Anderson Richard A | Screening method for identifying an agent that modulates PIPKIgamma trafficking of E-cadherin |
| ES2623447T3 (es) | 2007-12-19 | 2017-07-11 | Rhovac Aps | Inmunoterapia basada en RhoC |
| WO2009089040A1 (en) * | 2008-01-11 | 2009-07-16 | Jaffrey Samie R | Methods for expressing proteins in axons |
| EP2274617A4 (en) * | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
| BR112013026199A2 (pt) * | 2011-04-15 | 2017-11-07 | Compugen Ltd | polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US11957739B2 (en) | 2017-11-08 | 2024-04-16 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer using RHOA dominant negative forms |
-
2018
- 2018-11-05 US US16/761,540 patent/US11957739B2/en active Active
- 2018-11-05 JP JP2020520153A patent/JP2021502329A/ja active Pending
- 2018-11-05 CA CA3076269A patent/CA3076269A1/en active Pending
- 2018-11-05 AU AU2018365800A patent/AU2018365800A1/en not_active Abandoned
- 2018-11-05 CN CN201880066812.2A patent/CN111278443A/zh active Pending
- 2018-11-05 EP EP18875691.0A patent/EP3706751A4/en not_active Withdrawn
- 2018-11-05 WO PCT/US2018/059188 patent/WO2019094326A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sahin et al. | An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma | |
| Lhuillier et al. | Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control | |
| ES2988795T3 (es) | Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular | |
| CN104427992B (zh) | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 | |
| JP6945444B2 (ja) | 高親和性ｐｄ−１薬剤とその使用方法 | |
| JP7564122B2 (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| JP2021155442A (ja) | Ｎａｎｔ癌ワクチン | |
| JP2021520849A (ja) | 腫瘍特異的ｔ細胞受容体を得る方法 | |
| Meraz et al. | TUSC2 immunogene therapy synergizes with anti–PD-1 through enhanced proliferation and infiltration of natural killer cells in syngeneic Kras-mutant mouse lung cancer models | |
| JP2020514378A (ja) | 処置方法 | |
| US11219676B2 (en) | Methods of cancer treatment using tumor antigen-specific T cells | |
| CN110072550A (zh) | 用于治疗脑癌的组合疗法 | |
| JP2021502329A5 (https=) | ||
| Zhang et al. | In situ sting‐activating nanovaccination with tigit blockade for enhanced immunotherapy of anti‐Pd‐1‐resistant tumors | |
| TW201718852A (zh) | 具有病患衍生之異種移植物之非ｈｌａ配對的人源化ｎｓｇ小鼠模式 | |
| TW201742923A (zh) | 用於新抗原表位呈現的序列安排及序列 | |
| TW202320842A (zh) | 用於治療黑色素瘤之組合物及方法 | |
| US20230223105A1 (en) | Mitigation of statistical bias in genetic sampling | |
| WO2018148378A1 (en) | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy | |
| CN111148518A (zh) | 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法 | |
| JP2020524149A5 (https=) | ||
| US20230295734A1 (en) | Bcor rearrangements and uses thereof | |
| CN115803824A (zh) | 鉴定与临床反应相关的特征的方法及其用途 | |
| WO2022174234A2 (en) | Biomarkers for cancer treatment | |
| EP4416308A1 (en) | Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy |